Use of XXXX in the treatment of @entity9058 .

@entity1 @entity9058 @entity2879 @entity281 @entity1499
Five @entity1 with @entity9058 ( @entity9058 ), aged 6 weeks to 3 years, were treated with @entity2879 . The drug dosage ranged from 100 to 200 mg/m2 administered biweekly until remission was achieved, and then at 1- to 3-week intervals as maintenance therapy. Intrathecal @entity1499 was given to two @entity1 with central nervous system involvement. All @entity1 attained remission. Systemic relapses often ensued in all @entity1 when @entity2879 was delayed because of myelosuppression, or after attempts to lengthen the treatment interval, but they initially responded again to a more intensive chemotherapy schedule. To date, four of the @entity1 died from disseminated disease and @entity281 15 to 20 months from the time of diagnosis. One @entity1 is alive and well 20 months from diagnosis. Three of the dead @entity1 had become refractory to the drug. Our observations show that @entity2879 induces remissions and prolongs survival in @entity9058 . However, since the @entity1 eventually become refractory to the drug and die of the disease, additional forms of therapy are required to improve the outlook of affected @entity1 .
